tbuckley/cabot-search huggingface dataset:
SAT0320 Igg3 Autoantibodies Binding To Stathmin-4 as Marker of Polyneuropathy in Primary Sjögren Syndrome:
Authors: S. Ross, T. Witte, M. Stangel, R.E. Schmidt, N.T. Baerlecken
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Primary Sjögren-syndrome (pSS) is considered as autoimmune phenomena affecting exocrine glands with various clinical phenotyps. PSS can appear with different extraglandular manifestations such as arthritis, myositis, vasculitis and peripheral or central neuropathies. 8.5–67% of patients with pSS complain about neurological symptoms. About 9% can be diagnosed having a destinct form of polyneuropathy (PNP). <h3>Objectives</h3> Here, we investigated autoantibodies binding to stathmin-4 (STMN-4) in pSS with PNP. <h3>Methods</h3> We screened 4 versus 4 having pSS with and without PNP for discriminating autoantibodies by using protein array technology. We identified autoantibodies binding to STMN-4 in patients with pSS and PNP. We evaluated our finding by establishing different ELISA detections for STMN-4 autoantibodies using sera of different underlying diseases (n=484). <h3>Results</h3> Using Anti-IgG3 STMN-4, we tested the following groups. In pSS with PNP 33% had anti-IgG3 STMN-4 antibodies and 6% without PNP had anti-IgG3 STMN-4 (likelihood 5.5). Anti-IgG3 STMN is associated with PNP in pSS patiens (Fisher exact two-tailed p-value=0.016). We could not see any significant association in other diseases with PNP and metabolic or toxic induced PNP. <h3>Conclusions</h3> Anti-IgG3 STMN is a new potential marker for PNP in patients with pSS. <h3>References</h3> none <h3>Disclosure of Interest</h3> S. Ross Shareholder of: none, Grant/research support from: none, Consultant for: none, Employee of: none, Paid instructor for: none, Speakers bureau: none, T. Witte Shareholder of: none, Grant/research support from: none, Consultant for: none, Employee of: none, Paid instructor for: none, Speakers bureau: none, M. Stangel Shareholder of: none, Grant/research support from: none, Consultant for: none, Employee of: none, Paid instructor for: none, Speakers bureau: none, R. Schmidt Shareholder of: none, Grant/research support from: none, Consultant for: none, Employee of: none, Paid instructor for: none, Speakers bureau: none, N. Baerlecken Shareholder of: none, Grant/research support from: none, Consultant for: none, Employee of: none, Paid instructor for: none, Speakers bureau: none
AB0019 IL-10-Producing Bregs Are Decreased in Psoriatic Arthritis and Inversely Correlate with Th17 Cells
Authors: A. Mavropoulos, A. Varna, I. Alexiou, C. Liaskos, E. Zafiriou, M. Vlychou, D.P. Bogdanos, L.I. Sakkas
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> B cells may form ectopic lymphoid-like structures in the synovium of patients with psoriatic arthritis (PsA) but the significance of this finding is not clear. A recent study found high frequency of autoantibodies in PsA<sup>1</sup>. Whether regulatory B cells (Bregs) are decreased or not in PsA is not clear. <h3>Objectives</h3> To assess the phenotypic and functional characteristics of Breg subsets, CD19(pos)CD27(pos)CD24(high) memory and CD19(pos)CD24(high)CD38(high) transitional Bregs in patients with PsA. <h3>Methods</h3> Peripheral blood mononuclear cells, isolated from 61 PsA patients, 21 patients with psoriasis (Ps) and 15 normal controls (NCs), were assessed. The expression of surface CD19, CD24, CD27 and CD38 and cytoplasmic IL-10 by Bregs was examined by flow cytometry following 24 hour bacterial CpG (ODN2006) stimulation using fluorochrome-conjugated monoclonal antibodies. We also measured IL-17 expression from T cells (Th17 cells) stimulated with PMA plus Ionomycin for 5 hours followed by intracellular staining (BD Biosciences). <h3>Results</h3> Transitional Bregs were significantly decreased in PsA patients compared to NCs (0.72±0.54 <i>vs</i>1.56±0.58, <i>p</i>=0.000) and in Ps compared to NCs (1.08±0.38 <i>vs</i> 1.56±0.58, <i>p</i>=0.016, as well as in PsA compared to Ps patients (<i>p</i>=0.002). Memory Bregs were significantly decreased in PsA patients compared to NCs (2.93±2.31<i>vs</i> 6.94±2.03, <i>p</i>=0.000) and in Ps patients (2.97±1.83) compared to NCs (<i>p=</i>0.000) but did not differ between PsA and Ps patients. The impairment of Bregs in PsA was not associated with number of swollen or tender joints, CRP, ESR, or treatment with biologics. IL-10-producing Bregs inversely correlated with Th17 cells in PsA and in Ps. <h3>Conclusions</h3> PsA exhibits numerical decrease and functional impairment of Bregs, especially of transitional Bregs. IL-10-producing Bregs inversely correlate with Th17 cells. The impairment of IL-10-producing Bregs may contribute to the pathogenesis of psoriatic disease. <h3>References</h3> Dolcino M et al. PLoSone 2014;9:e115424 <h3>Acknowledgement</h3> Financial support by ELKE, University of Thessaly <h3>Disclosure of Interest</h3> None declared
AB0666 Progression of Aortic and Valve Abnormalities in Patients with Ankylosing Spondylitis
Authors: A. Godzenko, Y.O. Korsakova, A. Bochkova, O. Rumyantseva, V. Badokin, S. Erdes
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Aortic and valve abnormalities are systemic inflammatory manifestations of ankylosing spondylitis (AS). Data on the prevalence, clinical significance and evolution are discrepant. <h3>Objectives</h3> To assess the dynamics of aortic and valve abnormalities detected by transthoracal echocardiography (TTE) in AS pts according to the results of prospective study. <h3>Methods</h3> 45 pts with AS (The New-York criteria) age &lt;60 years, with the initial TTE - changes of aorta and valves and without concomitant cardiac diseases were assessed at the Institute of Rheumathology from 2008 to 2015. At baseline 15 pts had aortic root dilatation, 21 – aortic wall thickening, 32 – aortic valve thickening, 15 – mitral valve thickening. 5 pts had valve prosthesis (including 2 with both aortic and mitral prosthesis). 19 pts had aortic regurgitation (AR), 15 of them – 1–2 degree, 4 – 3–4 degree), 20 pts had mitral regurgitation (MR) 1–2 degree. Subaortic thickening ("bump") was detected in 10 pts. 16 of 45 pts used anti-TNF drugs during the observation period, 14 pts – only NSAID, 15 – NSAID and DMARD, including sulfaslazine (11 pts) and metotrexate (4 pts). All pts were underwent re-TTE after 1–4 years <h3>Results</h3> Negative dynamics was detected in 27 (60%) pts in total. Progression of aortic root dilatation from 1 to 6mm was detected in 12 of 15 pts (80%), in 2 - dilatation was first identified. 14 pts had first identified valve thickening (9 – aortic, 4 – mitral, 1 – both). 5 pts were underwent valve replacement: 4 – aortic, 1 – mitral. AR progression was detected in 10 pts (in 2 – of 2 degree, in 8 – of 1 degree), MR progression – in 6 pts of 1 degree). A negative correlation was found between anti-TNF- therapy and progression of aortic root dilatation (R=-0,329, P=0,03). "Subaortic bump" was first identified in 3 pts. Among 10 pts with subaortic bump initially, decrease from 8mm to 3mm was found in 1 pts, complete regression – in 2, all used biologics. <h3>Conclusions</h3> Aortic root and valve abnormalities tend to progression in most AS pts. Subaortic bump is able to regress if it is due to inflammatory edema and not fibrosis. Active anti-inflammatory therapy can protect in cardiac disease progression. <h3>References</h3> Klingberg E, Sveälv BG, Täng MS, Bech-Hanssen O, Forsblad-d9Elia H, Bergfeldt L. Aortic Regurgitation Is Common in Ankylosing Spondylitis: Time for Routine Echocardiography Evaluation Am J Med. 2015 Nov;128(11):1244–1250.e1. doi: 10.1016/j.amjmed.2015.04.032. Epub 2015 Jun 4. van der Horst-Bruinsma IE, Nurmohamed MT. Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2012 Dec;4(6):413–22. doi: 10.1177/1759720X12458372. <h3>Disclosure of Interest</h3> None declared
Pegylated Interferon Alpha – 2a in Patients with Myeloproliferative Neoplasms (MPN): International Experience in 115 Cases
Authors: Krisstina Gowin, Prakash Thapaliya, J Samuelson, C N Harrison, Deepti Radia, Bjorn Andreasson, John Mascarenhas, Alessandro Rambaldi, T Barbui, Catherine J Rea, John Camoriano, A Gentry, Jean-Jacques Kiladjian, Casey L O'Connell, Ruben A. Mesa
Journal: Blood (2011)
Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention
Authors: Kate Vandyke, Krzysztof M. Mrozik, Chee Man Cheong, Annie W.S. Chow, Chung H Kok, Orest Blaschuk, Jonathan D. Licht, Andrew C.W. Zannettino
Journal: Blood (2014)
Another Tattoo Reaction Pitfall
Authors: Rachel Cunningham, Jean Kemp, Leonard Sperling
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia
Authors: Isere Kuiatse, Sheeba K. Thomas, Donna M. Weber, Adam M. Stein, Michael Wang, Jatin J. Shah, Steven P. Treon, Stephen M. Ansell, Robert Z. Orlowski
Journal: Blood (2012)
Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP)
Authors: Jorge Cortes, Susan O’Brien, Gautam Borthakur, Dan Jones, Farhad Ravandi, Charles Koller, Ofelia Mesina, Alessandra Ferrajoli, Jianqin Shan, Hagop Kantarjian
Journal: Blood (2008)
PWE-148 Tackling The 2WW Service- A Hard Nut Cracked
Authors: S Vinnamala, A Gibson, L Osborne, J Akhtar, A Malik, SMT Nasser, J Mannath, J Eaden
Journal: Gut (2016)

<h3>Introduction</h3> A service review of the upper GI 2 WW referrals locally showed a 20% annual increase in the UGI referrals from 2013 to 2015. The cancer pick up rates were static at 4.5% with the vast majority of patients discharged back to their GP after a normal gastroscopy.<sup>1</sup> The review also showed a 43% re-referral rate back to gastroenterology after a normal gastroscopy leading to an increase in the outpatient volumes and hence a delay in the delivery of care to those patients. <h3>Methods</h3> We piloted a dedicated consultant taking a lead to vet all UGI referrals and to channel them in to a simple (straight to gastroscopy) or complex (clinic first) pathway. All complex pathway patients were reviewed in clinic and investigated appropriately if required. <h3>Results</h3> Of the 619 UGI 2 WW referrals received over a 3 month period between August to October 2015, 153 (25%) patients were reviewed in dedicated complex pathway clinics (2 clinics/week). The cancer pick up rate increased to 8% (12) with 60% (7) being UGI (oesophagus (6) and stomach (1)) and 40% Non-GI cancers (ovarian, lung and endometrial cancers). 15% of these patients had a diagnosis requiring ongoing secondary care follow up (more than one follow up appointment) for conditions such as strictures, coeliac disease and eosinophilic oesophagitis etc. 42% (65) had a clinically significant diagnosis that required advice and guidance to GP for community follow up. 82% were discharged back to primary care after one follow up appointment. <h3>Conclusion</h3> There was an 80% increase in the cancer pick up rate as compared to our previous direct to test pathway. We believe daily clinician vetting of referrals and upgrading to a clinic first pathway contributed to a higher rate of cancer detection. There were non GI cancers detected which would have been missed with a gastroscopy only service. The prompt clinic follow up in secondary care for patients with significant yet benign diagnoses together with advice and reassurance prior to discharge for others should eventually lead to a reduction in the re-referral rate whilst maintaining the high quality delivery of care. <h3>Reference</h3> 1 Kapoor N, Bassi A, Sturgess R, <i>et al</i>. Predictive value of alarm features in a rapid access upper gastrointestinal cancer service. <i>Gut</i> 2005;<b>54</b>:40–5. <h3>Disclosure of Interest</h3> None Declared
PTH-014 Food Bolus Obstruction: An Experience from A Large Teaching Hospital
Authors: CO Langoya, A O’connor, B Rembacken
Journal: Gut (2016)

<h3>Introduction</h3> Food bolus obstruction is a common problem encountered by endoscopists with an annual incidence estimated to be around 13 per 100,000.<sup>1</sup> Several means of endoscopic management have been proposed including extraction, using a snare or a roth net, or pushing, occasionally with dilatation. The aim of this audit was to determine the common types of foodstuffs causing food bolus obstruction (FBO), the prevalence of eosinophilic oesophagitis (EO) among those cases and how different endoscopists in St. James’ University Hospital, Leeds handle FBO cases in terms of treatment and subsequent endoscopy follow up. <h3>Methods</h3> Two years’ data (2014 and 2015) was retrieved from the endoscopy data base in St. James’ University Hospital and a total of 33 cases of endoscopy for food bolus obstruction within the specified period were generated and analysed. Excel was used to construct graphs and tables and draw the descriptive statistics (mean, standard deviation, mode and median) of variables. <h3>Results</h3> Younger males are found to be more likely affected than females or elderly patients. In 8 cases no food bolus was seen at endoscopy, leaving 25 cases for analysis. In 10 cases (40%) the type of food causing the bolus was not documented. Among the others in 11 cases meat was the cause, 3 times fish and only once vegetables. In 13 cases (52%) the bolus was retrieved with either a snare or Roth net. In 12 cases (48%) it was pushed through, having first been crushed in 5 of these cases. All attempts were successful with no serious adverse events. EO was diagnosed in 24% (n = 6). Reflux was present in 28% (n = 7). One patient had an oesophageal cancer. 4 patients had a pre-existing diagnosis of oesophageal cancer, 1 had a peptic oesophageal stricture and another had a radiation induced stricture. Paired biopsies from upper and lower oesophagus were taken in 68% (n = 17) of cases, of the other 8 five had already been given a histologic diagnosis for their oesophageal stricture (4 malignant, 1 benign) and biopsies were not judged to be needed. Eosinophilic oesophagitis was suspected endoscopically in five cases and confirmed histologically in four of those. In two cases, endoscopic appearances were normal and random paired biopsies identified eosinophilic oesophagitis. <h3>Conclusion</h3> FBO is a relatively uncommon presentation even in a large acute unit. The majority of cases are due to benign disease. Endoscopic treatment modalities vary and pushing and removal methods seem to be of equally of good efficacy and safety. Meat bolus is the commonest cause of food bolus obstruction. There is a good diagnostic yield from biopsy. <h3>Reference</h3> 1 Longstreth GF, Longstreth KJ, Yao JF. Esophageal food impaction: epidemiology and therapy. A retrospective, observational study. <i>Gastrointest Endosc</i>. 2001 Feb; <b>53</b>(2):193–8 <h3>Disclosure of Interest</h3> None Declared
OC-016 The Risk of Gastrointestinal Bleeding with Non-Vitamin K Antagonist, Oral Anticoagulant Medications. A Systematic Review and Network Meta-Analysis
Authors: N Burr, K Lummis, R Sood, A Corp, V Subramanian
Journal: Gut (2016)

<h3>Introduction</h3> The non-vitamin k antagonist (VKA) oral anticoagulants (NOAC) comprise inhibitors of thrombin and factor Xa. They are being increasingly used in patients requiring long-term anticoagulation due to non-inferiority and relative ease of use when compared to VKA and low molecular weight heparin (LMWH). Prospective randomised studies testing the efficacy of NOACs have shown a possible increased risk of gastrointestinal (GI) bleeding. To clarify the risk of GI bleeding we performed a systematic review and Bayesian network meta-analysis. <h3>Methods</h3> We followed a pre-specified and peer reviewed PRISMA extension guidelines and checklist for reporting systematic reviews and network meta-analyses. A comprehensive search of the literature was performed to identify any study, prospective or retrospective, which compared NOAC with VKA or LMWH and reported on GI bleeding. Studies on all indications for these medications were included. We did not include studies which compared against placebo or antiplatelet medication. We performed a Bayesian random effects regression model. To estimate the effect of NOAC on GI bleeding we calculated incidence rate ratios (IRR) based on the number of patient years exposed to the medication. We grouped medications together by mechanism of action; VKA, LMWH, thrombin inhibitor or factor Xa inhibitor. Pre-planned subgroup analyses were performed on; indication, population, study design, GI bleed definition and NOAC dose. <h3>Results</h3> We identified 35 studies reporting on 481, 534 patients exposed to 405, 026 patient years of anticoagulant medication. The overall GI bleeding incidence was 1.3 events per 100 patient years. We found no difference in the incidence rate of major GI bleeding when comparing NOAC medications with VKA and LMWH. This results was sustained on sensitivity analyses comparing observational and prospective trial data, the indication for anticoagulation and prophylactic versus therapeutic doses. When analysing all severities of GI bleeding, we found a statistically significant reduction when comparing Xa inhibitors with VKA (IRR 0.20, 95% CrI 0.05–0.65), and thrombin inhibitors (IRR 0.20, 95% CrI 0.05–0.67) respectively. <h3>Conclusion</h3> We have shown that there is no difference in the risk of major GI bleeding when comparing NOAC, VKA and LMWH anticoagulation medications. There is a significant reduction in all GI bleeding events with the use of factor Xa inhibitors when compared to VKA and direct thrombin inhibitors. <h3>Disclosure of Interest</h3> None Declared
Clinical and Immunophenotypic Differences of Patients with T/NK-Cell Large Granular Lymphocytic Leukemia
Authors: Yulia E Vinogradova, Irina N Lutsenko, Rima S Samoilova, Elena I Selivanova, Ivan A Vorobiev, Irina B Kaplanskaya, Natalia B Rijicova, Nelly G Gabeeva, Unan L Dzulakian, Lyuba Varticovski, Nikita E Shklovskiy-Kordi, Andrei I Vorobiev
Journal: Blood (2008)
Cardiac and Liver Magnetic Resonance Characterization of Thalassemia Intermedia Patients: A Comparative Multicenter Study Versus Thalassemia Major Patients
Authors: Alessia Pepe, Brunella Favilli, Anna Ramazzotti, Vincenzo Positano, Caterina Borgna-Pignatti, Marcello Capra, Maria-Eliana Lai, Anna Spasiano, Lorella Pitrolo, Aldo Filosa, Paolo Cianciulli, Antonietta Mascolino, Gaetano Giuffrida, Gianluca Forni, Aurelio Maggio, Massimo Lombardi
Journal: Blood (2008)
Multifunctional gold-nanoparticles: A nanovectorization tool for the targeted delivery of novel chemotherapeutic agents
Authors: Alexandra R. Fernandes, João Jesus, Pedro Martins, Sara Figueiredo, Daniela Rosa, Luísa M.R.D.R.S. Martins, Maria Luísa Corvo, Manuela C. Carvalheiro, Pedro M. Costa, Pedro V. Baptista
Journal: Journal of Controlled Release (2016)
Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies
Authors: Herve Ghesquieres, Beth R Larrabee, Olivier Casasnovas, Matthew J Maurer, Stephen M. Ansell, Aurelie Verney, Susan L Slager, Pauline Brice, Cristine Allmer, Franck Morschhauser, Thomas M Habermann, Isabelle Gaillard, Yan W Asmann, Brian K Link, Aspasia Stamatoullas, Christophe Ferme, Ahmet Dogan, Josee Audouin, James R Cerhan, Gilles Salles
Journal: Blood (2012)
AB0834 Acute Calcium Pyrophosphate Crystal Arthritis as A Cause of Sudden Onset of Fever and Arthritis in Geriatric Patients
Authors: Y. Yamamura, K. Fujita, N. Shibutou, A. Ueno, M. Yamamura
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Calcium pyrophosphate (CPP) deposition may give rise to clinical presentations that mimic septic arthritis, polyarticular inflammatory arthritis or osteoarthritis. Of 4 different presentations<sup>1)</sup>, acute CPP crystal arthritis crystal arthritis, also known as pseudogout, is characterized by sudden attacks of arthritis frequently with systemic inflammatory features such as fever. <h3>Objectives</h3> To determine clinical findings of patients with acute CPP crystal arthritis who was hospitalized due to fever of unknown origin or developed during hospitalization from 2011 to 2015. <h3>Methods</h3> Patients were diagnosed as having acute CPP crystal arthritis according to the diagnostic criteria proposed by McCarty DJ<sup>2)</sup> and classification of clinical presentations proposed by EULAR recommendation<sup>1)</sup>. <h3>Results</h3> We enrolled 26 patients with acute CPP crystal arthritis who were classified as described above, including 9 males and 17 females. All patients presented acute attacks of arthritis. Eight patients were hospitalized due to high fever; and others were for infections in 8 patients, strokes in 6, malignancies in 2 and other medial illnesses in 4, followed by arthritis or fever. The median age at diagnosis was 83.5 years (range 69–102). Fever (&gt;37.5°C) developed in 17 patients and the mean CRP level (± SD) was 14.6±7.2 mg/dL (2.08 - 28.88; n=23). Ten patients were polyarticular or oligoarticular while 16 patients were monoarticular; and affected joints included knee joints in 18 patients, wrist in 6, ankle in 6, elbow in 3, shoulder in 2, cervical in 2, and finger in 2. CPP crystals were demonstrated in synovial fluids in 12 of 15 patients with arthrocentesis. The presence of CPPD deposition-related arthropathy including chondrocalcinosis was found in 24 patients by radiographic studies. All patients responded well to treatment including non-steroidal anti-inflammatory drugs (n=16), joint aspiration and rest (n=5), oral colchicine (n=3), intraarticular injection of glucocorticoids (n=3) and parenteral glucocorticoids (n=2; prednisolone 30 mg/day). <h3>Conclusions</h3> The results indicates that acute CPP crystal arthritis develops in not rarely the geriatric population over 75 years of age, often leading to sudden onset of fever and disability. It should be noted that these attacks are often provoked by severe medical diseases such as infections and strokes. <h3>References</h3> Zhang W, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011;70:563–70. McCarty DJ. Crystals and arthritis. Dis Mon 1994;255–99. <h3>Disclosure of Interest</h3> None declared